Cost-effectiveness of widespread screening for Chlamydia trachomatis

Maarten J Postma*, Robert Welte, Servaas A Morré

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    3 Citations (Scopus)

    Abstract

    Screening for sexually transmitted diseases is included in routine health care for several infectious agents in many western European countries. Current considerations on extensions of these programs include widespread screening strategies for Chlamydia trachomatis. In women, C. trachomatis infection may lead to sequelae such as infertility and ectopic pregnancy. This paper reviews the goal of screening and subsequent therapy and the available compounds for testing and treating. Furthermore, the current best practice - in particular with respect to economic performance - is discussed, and those factors that most crucially influence the economic profile are described. Illustrations are drawn from recent work in The Netherlands, which may also be representative for other settings.

    Original languageEnglish
    Pages (from-to)1443-1450
    Number of pages8
    JournalEXPERT OPINION ON PHARMACOTHERAPY
    Volume3
    Issue number10
    DOIs
    Publication statusPublished - Oct-2002

    Keywords

    • Chlamydia Infections
    • Chlamydia trachomatis
    • Cost-Benefit Analysis
    • Female
    • Humans
    • Male
    • Mass Screening
    • Netherlands
    • Pregnancy

    Cite this